Tyrosine Kinase Inhibitors (tkis) - Pharma

Relevant Publications

Tanreqing injection inhibits stemness and enhances sensitivity of non-small cell lung cancer models to gefitinib through ROS/STAT3 signaling pathway.

Issue Release: 2024

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.

Issue Release: 2024

Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.

Issue Release: 2024

Derivatives of D(-) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-I: Synthesis, biological screening and in silico binding interaction analysis.

Issue Release: 2024

Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors.

Issue Release: 2024

New Insights of Target Therapy: Effects of Tyrosine Kinase Inhibitors on Male Gonadal Function: A Systematic Review.

Issue Release: 2024

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.

Issue Release: 2024

Cancer mutational signatures identification in clinical assays using neural embedding-based representations.

Issue Release: 2024

CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study.

Issue Release: 2024

Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 1: Dosage form design, and models of expansion, post-expansion mechanical strength, and drug release.

Issue Release: 2024

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC.

Issue Release: 2024

Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms.

Issue Release: 2024

Pharmacotherapy and cardiovascular challenges: a case report of olverembatinib-induced myocardial infarction with non-obstructive coronary arteries.

Issue Release: 2024

Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review.

Issue Release: 2024

Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive -mutant Non-small Cell Carcinoma.

Issue Release: 2024

Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia.

Issue Release: 2024

Pathways and targeting avenues of BRAF in non-small cell lung cancer.

Issue Release: 2024

Strategies for Enhancing Non-small Cell Lung Cancer Treatment: Integrating Chinese Herbal Medicines with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Therapy.

Issue Release: 2024

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

Issue Release: 2024

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Issue Release: 2024

How Can Technology Aid in Management?

What is Cellular Stress?

Why is Regulatory Approval Important?

What are the Key Cellular Stress Pathways?

What is Medication Adherence?

What are Collaborative Care Models?

What is Regulatory Approval?

What is Pharma?

How Are Participants Protected?

What Should Be Included in Patient Education Materials?

Tyrosine Kinase Inhibitors (tkis) - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics